Evaluating neurotoxicities following CAR-T therapy

Results of a French study performed at centers in Paris, Nantes, Lyon, Montpellier, and Rennes, show that about 40% of patients with lymphoma treated with chimeric antigen receptor-modified T-cell (CAR-T) therapy have neurotoxicities following infusion.